For instance, in patients with NSCLC with high PD-L1 expression treated with pembrolizumab (a PD-1 inhibitor), the five-year overall survival (OS) rate is approximately 25–30% (6). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.